Blarcamesine works better when taken earlier in Alzheimer's: Study
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
The Alzheimer's Association is urging patients, caregivers, and advocates to "take action now" and support legislation this awareness month.| Alzheimer's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase 3 trial goals for improving cognition and daily function. In REFOCUS-ALZ (NCT05026177), patients treated with simufilam showed no significant improvements in cognitive functioning, as […] The post Simufilam fails to meet Phase 3 trial goals; development discontinued appeared first on Alzheime...| Alzheimer's News Today – The Web's Daily Resource for Alzheimer's News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Alzheimer's News Today
Early menopause and poor brain-connection health may interact to increase Alzheimer's disease risk in women, a study found.| Alzheimer's News Today
The U.S. FDA has approved monthly maintenance dosing for Leqembi, a treatment for early Alzheimer’s disease.| Alzheimer's News Today
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ADVANCE-2 didn't.| Alzheimer's News Today
Patricia Inacio is a science writer for Alzheimer's News Today with a PhD in cell biology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Lindsey Shapiro is a science writer for Alzheimer's News Today with a PhD in neuroscience. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Marisa Wexler is a senior science writer for Alzheimer's News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Margarida Maia is a science writer for Alzheimer's News Today with a PhD in biomedical sciences. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
